Mucoactive Agents for Airway Mucus Hypersecretory Diseases

Total Page:16

File Type:pdf, Size:1020Kb

Mucoactive Agents for Airway Mucus Hypersecretory Diseases Mucoactive Agents for Airway Mucus Hypersecretory Diseases Duncan F Rogers PhD FIBiol Introduction Sputum Profile of Airway Inflammation and Mucus Hypersecretory Phenotype in Asthma, COPD, and CF Which Aspect of Airway Mucus Hypersecretion to Target? Theoretical Requirements for Effective Therapy of Airway Mucus Hypersecretion Current Recommendations for Clinical Use of Mucolytic Drugs Mucoactive Drugs N-Acetylcysteine: How Does it Work? Does it Work? Dornase Alfa Hypertonic Saline Surfactant Analysis Summary Airway mucus hypersecretion is a feature of a number of severe respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis (CF). However, each disease has a different airway inflammatory response, with consequent, and presumably linked, mucus hypersecretory phenotype. Thus, it is possible that optimal treatment of the mucus hyper- secretory element of each disease should be disease-specific. Nevertheless, mucoactive drugs are a longstanding and popular therapeutic option, and numerous compounds (eg, N-acetylcysteine, erdosteine, and ambroxol) are available for clinical use worldwide. However, rational recommen- dation of these drugs in guidelines for management of asthma, COPD, or CF has been hampered by lack of information from well-designed clinical trials. In addition, the mechanism of action of most of these drugs is unknown. Consequently, although it is possible to categorize them according to putative mechanisms of action, as expectorants (aid and/or induce cough), mucolytics (thin mucus), mucokinetics (facilitate cough transportability), and mucoregulators (suppress mechanisms underlying chronic mucus hypersecretion, such as glucocorticosteroids), it is likely that any bene- ficial effects are due to activities other than, or in addition to, effects on mucus. It is also noteworthy that the mucus factors that favor mucociliary transport (eg, thin mucus gel layer, “ideal” sol depth, and elasticity greater than viscosity) are opposite to those that favor cough effectiveness (thick mucus layer, excessive sol height, and viscosity greater than elasticity), which indicates that differ- Duncan F Rogers PhD FIBiol is affiliated with the National Heart & The author reports no conflicts of interest related to the content of this Lung Institute, Imperial College London, Dovehouse Street, London, paper. United Kingdom. Dr Rogers presented a version of this paper at the 39th RESPIRATORY Correspondence: Duncan F Rogers PhD FIBiol, Airway Disease, Na- CARE Journal Conference, “Airway Clearance: Physiology, Pharmacol- tional Heart & Lung Institute, Imperial College London, Dovehouse ogy, Techniques, and Practice,” held April 21–23, 2007, in Cancu´n, Street, London SW3 6LY, United Kingdom. E-mail: duncan.rogers@ Mexico. imperial.ac.uk. 1176 RESPIRATORY CARE • SEPTEMBER 2007 VOL 52 NO 9 MUCOACTIVE AGENTS FOR AIRWAY MUCUS HYPERSECRETORY DISEASES ent mucoactive drugs would be required for treatment of mucus obstruction in proximal versus distal airways, or in patients with an impaired cough reflex. With the exception of mucoregulatory agents, whose primary action is unlikely to be directed against mucus, well-designed clinical trials are required to unequivocally determine the effectiveness, or otherwise, of expectorant, mucolytic, and mucokinetic agents in airway diseases in which mucus hypersecretion is a pathophysiological and clinical issue. It is noteworthy that, of the more complex molecules in development, it is simple inhaled hypertonic saline that is currently receiving the greatest attention as a mucus therapy, primarily in CF. Key words: mucus, hypersecretion, asthma, chronic obstructive pulmonary disease, COPD, cystic fibrosis, mucolytic, mucokinetic, expectorant, mucoactive, N-acetylcysteine, erdosteine, ambroxol. [Respir Care 2007;52(9):1176–1193. © 2007 Daedalus Enterprises] Introduction treat the disease, especially if the changes that have led to increased mucus production are irreversible. Nevertheless, Patients with asthma, chronic obstructive pulmonary dis- as discussed above, mucus hypersecretion does contribute ease (COPD), or cystic fibrosis (CF) invariably exhibit to clinical symptoms in certain groups of patients with characteristics of airway mucus hypersecretion, namely asthma, COPD, or CF. This suggests that it is important to sputum production,1,2 excessive mucus in the airway lu- develop drugs that address the airway mucus problem in men3 (Figs. 1 and 2), goblet cell hyperplasia,3–6 and sub- these patients. There are 2 points that need considering mucosal gland hypertrophy.3,5 The pathophysiological se- when developing drugs aimed at reducing airway hyper- quelae of mucus hypersecretion are airway obstruction, secretion: airflow limitation, ventilation-perfusion mismatch, and im- • The nature of the underlying disease process in asthma, pairment of gas exchange. In addition, compromised mu- COPD, and CF, and how this relates to the mucus hy- cociliary function, with reduced mucus clearance, can en- persecretory phenotype in each condition courage bacterial colonization, leading to repeated chest infections and exacerbations, particularly in COPD and • The aspect(s) of mucus hypersecretion that should be CF. In COPD, a city-wide epidemiological study in Copen- targeted hagen showed that a number of clinical variables, includ- This paper considers the validity of using compounds ing deterioration in lung function, risk of hospitalization, with potential beneficial effects on airway mucus as treat- and risk of death, were greater in patients with COPD who ments in asthma, COPD, and CF. To set these drugs in had chronic mucus hypersecretion, compared with patients context, the paper begins with discussion of sputum, air- with either no sputum production or with only a small way mucus, and mucins, followed by an outline of the amount of intermittent sputum production7 (Fig. 3). In characteristics of mucus hypersecretion in asthma, COPD, addition, patients who had chronic airway mucus hyper- and CF, and emphasizes differences between the 3 condi- secretion and were also susceptible to chest infections had tions, and the theoretical requirements for drugs aimed at greater mortality and morbidity, compared with patients effectively inhibiting airway mucus hypersecretion. with mucus hypersecretion but without infections (see Fig. 3). In contrast, the contribution of mucus to patho- physiology and clinical symptoms in asthma or CF is less Sputum well defined. In asthma, excess mucus may not only ob- struct the airway lumen, but also contribute to the devel- Coughing or “hawking” to bring up “phlegm” is a sign opment of airway hyperresponsiveness.8 The latter possi- of respiratory disease.2,10 It indicates airway mucus hyper- bilities led to the suggestion that chronic mucus secretion, coupled with impaired mucus clearance and mu- hypersecretion reflects lack of asthma control, leading in cus retention, and is an aspect of many lung infections, turn to accelerated loss of lung function and increased asthma, COPD, bronchiectasis, and CF. The expectorated mortality.7 In CF, mucus accumulation is associated with excessive secretions are referred to as sputum. The char- airway obstruction and with bacterial colonization of the acteristics of mucus change with infection and inflamma- airways, leading to cycles of infection and exacerbations.9 tion. Inflammation leads to mucus hypersecretion, ciliary The association of airway mucus hypersecretion with dysfunction, and changes in the composition and biophys- asthma, COPD, and CF does not necessarily imply causa- ical properties of airway secretions.11 Inflammatory cells, tion. The excess mucus may merely be a result of the particularly neutrophils, which are recruited to the airway inflammatory processes that cause the disease. Conse- to combat infection, disappear from the airway, either quently, treating the mucus problem will not inevitably through programmed cell death (apoptosis) or by necrosis. RESPIRATORY CARE • SEPTEMBER 2007 VOL 52 NO 9 1177 MUCOACTIVE AGENTS FOR AIRWAY MUCUS HYPERSECRETORY DISEASES Fig. 1. Airway luminal mucus in respiratory diseases. A: Mucus (M) secretions (arrow) in an intrapulmonary bronchus in a patient with asthma. B: Airway mucus “tethering” in asthma. Transverse section through a bronchiole of a patient with asthma, showing incomplete release, or “continuity,” of secreted mucin from airway epithelial goblet cells (arrows). Similar appearances of mucus tethering are not observed in chronic obstructive pulmonary disease (COPD). E ϭ epithelium. C: Mucopurulent secretions in an intrapulmonary bronchus in a patient with COPD. D: Mucus (M) occluding a bronchiole in a patient with cystic fibrosis (CF). E ϭ epithelium. Necrotic neutrophils release pro-inflammatory mediators differences in the features of mucus obstruction in differ- that damage the epithelium and recruit more inflammatory ent hypersecretory conditions. cells. They also release deoxyribonucleic acid (DNA)12 First, although the underlying pulmonary inflammation and filamentous actin (F-actin) from the cytoskeleton. DNA of asthma, COPD, and CF shares many common features, and F-actin copolymerize to form a second rigid network there are specific characteristics unique to each condi- within airway secretions13,14 (Fig. 4). Neutrophil-derived tion.15–17 Asthma is usually an allergic disease that affects myeloperoxidase imparts a characteristic green color to the airways, rather than the lung parenchyma, and in gen- inflamed airway
Recommended publications
  • More Than Expectorant: New Scientific Data on Ambroxol in the Context of the Treatment of Bronchopulmonary Diseases
    Mini Review iMedPub Journals Journal of Intensive and Critical Care 2017 www.imedpub.com ISSN 2471-8505 Vol. 3 No. 3: 37 DOI: 10.21767/2471-8505.100096 More than Expectorant: New Scientific Data Manuel Plomer1* and 2 on Ambroxol in the Context of the Treatment Justus de Zeeuw of Bronchopulmonary Diseases 1 Medical Affairs CHC Germany, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, D-65926, Frankfurt am Main, Deutschland, German Abstract 2 Medical Specialist for Internal Medicine, Pneumology and Sleep Medicine, Background:Ambroxol has been established for decades in the treatment of Cologne, Germany, German acute and chronic respiratory diseases. A reassessment of the benefit-risk was conducted recently. Objective: What new scientific data, relevant for the treatment of *Corresponding author: bronchopulmonary diseases, were published in the last decade? Dr. Manuel Plomer Method: Systematic literature search via http://www.pubmed.gov with the search term “ambroxol”, covering the publication period from 2006 to 2015. Non- [email protected] relevant publications were excluded manually. Medical Manager, Medical Affairs CHC Results: 64 relevant publications could be identified covering both, clinical and Germany, Sanofi-Aventis Deutschland GmbH, preclinical research. Industriepark Höchst, D-65926 Frankfurt am Conclusion: The traditional indication of ambroxol as an expectorant is confirmed Main, Germany. but new results revealed a better understanding of the various mechanisms of action of ambroxol and the benefits for special patient populations. The Tel: 49 69 305 36803 available data suggest the use of ambroxol as an adjuvant in anti-infective therapy, particularly in case of infections with biofilm-producing pathogens. Lung- protective properties are discussed in both infants and severely ill adult patients.
    [Show full text]
  • European Journal of Scientific Exploration Vol 3 №2 2020
    EUROPEAN JOURNAL OF SCIENTIFIC EXPLORATION VOL 3 №2 2020 Determination of Oligomer Content in Benzonatate Drug Substance by HPLC Lakshmi Narasimha Rao Katakam 1 Santhosh Kumar Ettaboina 2 Thirupathi Dongala 2 1Saptalis Pharmaceuticals LLC, New York, USA 2Aurex Pharmaceuticals Inc, East Windsor, USA Abstract. A reverse-phase liquid chromatographic method has developed and validated to determine oligomer content in Benzonatate Drug substances. This method has a separation of relatively few monomer units, which constitutes an oligomer with a minimum adequate chromatographic resolution of 1.0 from each of the subject component peaks. The separation achieved using Phenomenex Luna C18 (250 X 4.6 mm) 5 µm column at a flow rate of 1.0 ml/min with an isocratic elution method. The mobile phase consisting of 0.25% Ammonium formate buffer and methanol in the ratio 350:650 (v/v), respectively. The Oligomer compounds detection carried out at UV 310 nm, and the LC method validated as per the current ICH Q2 guidelines. The method is effectively validated and proved to be precise, specific, linear, robust, and rugged to quantitate oligomer content in Benzonatate drug substance. Key words: benzonatate (BNZ), oligomers, HPLC, method validation. Introduction Benzonatate (BNZ) is an oral antitussive drug used to relieve and suppress cough in patients older than ten years of age (Oligomer Wikipedia, 2020). Currently, BNZ is the only non-narcotic antitussive available as a prescription drug. The chemical structure resembles that of the anesthetic agents in the para-amino-benzoic acid class (such as procaine and tetracaine), BNZ exhibits anesthetic or numbing action. BNZ also inhibits the transmission of impulses of the cough reflex in the medulla's vagal nuclei (Tessalon, 2020).
    [Show full text]
  • Appendix on Tariff Elimination Schedule for Mercosur
    Trade part of the EU-Mercosur Association Agreement Without Prejudice Disclaimer: In view of the Commission's transparency policy, the Commission is publishing the texts of the Trade Part of the Agreement following the agreement in principle announced on 28 June 2019. The texts are published for information purposes only and may undergo further modifications including as a result of the process of legal revision. However, in view of the growing public interest in the negotiations, the texts are published at this stage of the negotiations for information purposes. These texts are without prejudice to the final outcome of the agreement between the EU and Mercosur. The texts will be final upon signature. The agreement will become binding on the Parties under international law only after completion by each Party of its internal legal procedures necessary for the entry into force of the Agreement (or its provisional application). AR applied BR applied PY applied UY applied Mercosur Final NCM Description Comments tariff tariff tariff tariff Offer 01012100 Pure-bred horses 0 0 0 0 0 01012900 Lives horses, except pure-bred breeding 2 2 2 2 0 01013000 Asses, pure-bred breeding 4 4 4 4 4 01019000 Asses, except pure-bred breeding 4 4 4 4 4 01022110 Purebred breeding cattle, pregnant or lactating 0 0 0 0 0 01022190 Other pure-bred cattle, for breeding 0 0 0 0 0 01022911 Other bovine animals for breeding,pregnant or lactating 2 2 2 2 0 01022919 Other bovine animals for breeding 2 2 2 2 4 01022990 Other live catlle 2 2 2 2 0 01023110 Pure-bred breeding buffalo, pregnant or lactating 0 0 0 0 0 01023190 Other pure-bred breeding buffalo 0 0 0 0 0 01023911 Other buffalo for breeding, ex.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Xifaxan® (Rifaximin)
    Wednesday, October 14, 2015 4 p.m. Oklahoma Health Care Authority 4345 N. Lincoln Blvd. Oklahoma City, OK 73105 The University of Oklahoma Health Sciences Center COLLEGE OF PHARMACY PHARMACY MANAGEMENT CONSULTANTS MEMORANDUM TO: Drug Utilization Review Board Members FROM: Bethany Holderread, Pharm.D. SUBJECT: Packet Contents for Board Meeting – October 14, 2015 DATE: October 1, 2015 NOTE: The DUR Board will meet at 4:00 p.m. The meeting will be held at 4345 N Lincoln Blvd. Enclosed are the following items related to the October meeting. Material is arranged in order of the agenda. Call to Order Public Comment Forum Action Item – Approval of DUR Board Meeting Minutes – Appendix A Action Item – Vote on 2016 Meeting Dates – Appendix B Update on Medication Coverage Authorization Unit/Bowel Preparation Medication Post-Educational Mailing – Appendix C Action Item – Vote to Prior Authorize Tykerb® (Lapatinib), Halaven® (Eribulin), Ixempra® (Ixabepilone), Kadcyla® (Ado-Trastuzumab), Afinitor® (Everolimus), & Perjeta® (Pertuzumab) – Appendix D Action Item – Vote to Prior Authorize Orkambi™ (Lumacaftor/Ivacaftor) – Appendix E Action Item – Vote to Prior Authorize Savaysa® (Edoxaban) – Appendix F Action Item – Vote to Prior Authorize Epanova® (Omega-3-Carboxylic Acids), Praluent® (Alirocumab), & Repatha™ (Evolocumab) – Appendix G Annual Review of Constipation and Diarrhea Medications and 30-Day Notice to Prior Authorize Movantik™ (Naloxegol), Viberzi™ (Eluxadoline), & Xifaxan® (Rifaximin) – Appendix H 30-Day Notice to Prior Authorize Daraprim® (Pyrimethamine) – Appendix I Annual Review of Allergy Immunotherapies and 30-Day Notice to Prior Authorize Oralair® (Sweet Vernal, Orchard, Perennial Rye, Timothy, & Kentucky Blue Grass Mixed Pollens Allergen Extract) – Appendix J Annual Review of Non-Steroidal Anti-Inflammatory Drugs and 30-Day Notice to Prior Authorize Dyloject™ (Diclofenac Sodium) – Appendix K ORI-4403 • P.O.
    [Show full text]
  • Bronchiectasis (Non-Cystic Fibrosis), Acute Exacerbation: Antimicrobial Prescribing Evidence Review
    N ational Institute for Health and Care Excellence Final Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing Evidence review NICE guideline NG117 December 2018 Final Disclaimer The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian. Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties. NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the Welsh Government, Scottish Government, and Northern Ireland Executive. All NICE guidance is subject to regular review and may be updated or withdrawn. Copyright © National Institute for Health and Care Excellence, 2018. All rights reserved.
    [Show full text]
  • Drug Consumption in 2017 - 2020
    Page 1 Drug consumption in 2017 - 2020 2020 2019 2018 2017 DDD/ DDD/ DDD/ DDD/ 1000 inhab./ Hospital 1000 inhab./ Hospital 1000 inhab./ Hospital 1000 inhab./ Hospital ATC code Subgroup or chemical substance day % day % day % day % A ALIMENTARY TRACT AND METABOLISM 322,79 3 312,53 4 303,08 4 298,95 4 A01 STOMATOLOGICAL PREPARATIONS 14,28 4 12,82 4 10,77 6 10,46 7 A01A STOMATOLOGICAL PREPARATIONS 14,28 4 12,82 4 10,77 6 10,46 7 A01AA Caries prophylactic agents 11,90 3 10,48 4 8,42 5 8,45 7 A01AA01 sodium fluoride 11,90 3 10,48 4 8,42 5 8,45 7 A01AA03 olaflur 0,00 - 0,00 - 0,00 - 0,00 - A01AB Antiinfectives for local oral treatment 2,36 8 2,31 7 2,31 7 2,02 7 A01AB03 chlorhexidine 2,02 6 2,10 7 2,09 7 1,78 7 A01AB11 various 0,33 21 0,21 0 0,22 0 0,24 0 A01AD Other agents for local oral treatment 0,02 0 0,03 0 0,04 0 - - A01AD02 benzydamine 0,02 0 0,03 0 0,04 0 - - A02 DRUGS FOR ACID RELATED DISORDERS 73,05 3 71,13 3 69,32 3 68,35 3 A02A ANTACIDS 2,23 1 2,22 1 2,20 1 2,30 1 A02AA Magnesium compounds 0,07 22 0,07 22 0,08 22 0,10 19 A02AA04 magnesium hydroxide 0,07 22 0,07 22 0,08 22 0,10 19 A02AD Combinations and complexes of aluminium, 2,17 0 2,15 0 2,12 0 2,20 0 calcium and magnesium compounds A02AD01 ordinary salt combinations 2,17 0 2,15 0 2,12 0 2,20 0 A02B DRUGS FOR PEPTIC ULCER AND 70,82 3 68,91 3 67,12 3 66,05 4 GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 0,17 7 0,74 4 1,10 4 1,11 5 A02BA02 ranitidine 0,00 1 0,63 3 0,99 3 0,99 4 A02BA03 famotidine 0,16 7 0,11 8 0,11 10 0,12 9 A02BB Prostaglandins 0,04 62
    [Show full text]
  • Influence of Erdosteine, a Mucolytic Agent, on Amoxycillin Penetration Into Sputum in Patients with an Infective Exacerbation of Chronic Bronchitis
    Thorax: first published as 10.1136/thx.43.8.585 on 1 August 1988. Downloaded from Thorax 1988;43:585-590 Influence of erdosteine, a mucolytic agent, on amoxycillin penetration into sputum in patients with an infective exacerbation of chronic bronchitis GIOVANNI RICEVUTI, ANTONINO MAZZONE, ELVIRA UCCELLI, GABRIELLA GAZZANI, GIANCARLO B FREGNAN From the Section ofMedical Pathology I, Department ofInternal Medicine and Therapeutics, University of Pavia; the Department ofPharmaceutical Chemistry, University ofPavia; and the Research Center Laboratories, Ednond Pharma SRL, Milan, Italy ABSTRACT Twenty four patients with acute infective exacerbations of chronic bronchitis received amoxycillin alone or in combination with erdosteine (a mucolytic agent) for a week in a double blind, placebo controlled study. Clinical assessment scores, body temperature, serum and sputum amoxycillin concentrations, and sputum culture results were recorded in each group. Erdosteine significantly increased antibiotic concentrations in sputum but not in serum. The combined treatment also caused a more rapid decrease in sputum viscosity and in body temperature and faster sterilisation of the sputum. These results show that erdosteine increases amoxycillin concentration in sputum in patients with acute exacerbations ofchronic bronchitis. This effect may be due to a reduction in the viscosity of the bronchial secretions produced by erdosteine. copyright. Introduction Methods Although the exact role ofbacterial infections in acute PATIENTS exacerbations of chronic bronchitis is not clear, Twenty four patients (10 male and 14 female, aged 45- antibiotic treatment is widely used. In some patients, 71 years) with chronic bronchitis were studied during http://thorax.bmj.com/ however, the high viscosity ofthe bronchial secretions an acute, severe infective exacerbation.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,314.465 B2 Brew Et Al
    US009314465B2 (12) United States Patent (10) Patent No.: US 9,314.465 B2 Brew et al. (45) Date of Patent: *Apr. 19, 2016 (54) DRUG COMBINATIONS AND USES IN 2008.0003280 A1 1/2008 Levine et al. ................. 424/456 TREATING A COUGHING CONDITION 2008/O176955 A1 7/2008 Hecket al. 2008, 0220078 A1 9, 2008 Morton et al. (71) Applicant: Infirst Healthcare Limited 2009, O136427 A1 5/2009 Croft et al. 2009, O220594 A1 9, 2009 Field (72) Inventors: John Brew, London (GB); Robin Mark 2012/O128738 A1 5, 2012 Brew et al. Bannister, London (GB) 2012fO252824 A1 10/2012 Brew et al. (73) Assignee: Infirst Healthcare Limited, London FOREIGN PATENT DOCUMENTS (GB) CN 1593451 3, 2005 CN 101024.014 A 8, 2007 (*) Notice: Subject to any disclaimer, the term of this CN 101112383 B 5, 2010 patent is extended or adjusted under 35 DE 4420708 A1 12, 1995 U.S.C. 154(b) by 0 days. EP 2050435 B1 4/2009 GB 2114001 A 8, 1983 This patent is Subject to a terminal dis GB 2284761 A 6, 1995 claimer. GB 2424.185 B 9, 2006 GB 2442828 A 4/2008 JP 62-249924 A 10, 1987 (21) Appl. No.: 14/287,014 JP H1O-316568 A 12/1998 JP 2001-518928 A 10, 2001 (22) Filed: May 24, 2014 JP 200219.3839. A T 2002 JP 2003-012514 A 1, 2003 (65) Prior Publication Data JP 20030552.58 A 2, 2003 JP 2003128549 A 5, 2003 US 2014/O256750 A1 Sep. 11, 2014 JP 2003-321357 A 11, 2003 JP 2005-516917 A 6, 2005 JP 2008O31146 A 2, 2008 Related U.S.
    [Show full text]
  • UNIVERSITE DE NANTES Thomas Gelineau
    UNIVERSITE DE NANTES __________ FACULTE DE MEDECINE __________ Année 2011 N° 139 THESE pour le DIPLÔME D’ÉTAT DE DOCTEUR EN MÉDECINE DES de médecine générale par Thomas Gelineau né le 29 janvier 1983 à Cholet __________ Présentée et soutenue publiquement le 06/12/2011 __________ LE RHUME DE L'ENFANT ET SON TRAITEMENT: DECISION PARTAGEE AVEC LES PARENTS D'APRES UN QUESTIONNAIRE __________ Président : Monsieur le Professeur Olivier MALARD Directeur de thèse : Madame le Professeur Jacqueline LACAILLE 1 Table des matières IIntroduction................................................................................................................ 7 IIDéfinition, état des connaissances...........................................................................8 1Le rhume.......................................................................................................................................8 APhysiopathologie............................................................................................................................. 8 aL'origine virale.................................................................................................................................... 8 bLa saisonnalité................................................................................................................................... 8 cL'âge de survenue.............................................................................................................................. 9 dLe sexe..................................................................................................................................................
    [Show full text]
  • Erdosteine: Antitussive and Anti-Inflammatory Effects
    Lung (2008) 186 (Suppl 1):S70–S73 DOI 10.1007/s00408-007-9065-3 Erdosteine: Antitussive and Anti-inflammatory Effects Roberto W. Dal Negro Received: 31 July 2007 / Accepted: 4 October 2007 / Published online: 10 January 2008 Ó Springer Science+Business Media, LLC 2008 Abstract Erdosteine is a multifactorial drug currently used unresponsive to b2 adrenergics. This peculiar activity of in COPD for its rheologic activity on bronchial secretions erdosteine (to our knowledge never previously assessed) and its positive effects on bacterial adhesiveness. Erdosteine proved related to the ROS scavenging activity (which produces an active metabolite (Met 1) which was shown to actually proved equal to that of N), and its significant produce antioxidant effects during the respiratory burst of inhibiting effect on lipoperoxidation (8-isoprostane) proved human PMNs, due to the presence of an SH group. The discriminant between treatments, with antioxidant and anti- substantial antitussive effects of erdosteine were first docu- inflammatory effects the main determinants of the erdosteine mented in clinical trials even though mucolytic agents are multifactorial properties. In addition, antitussive effects may regarded as not consistently effective in ameliorating cough be regarded as related to its anti-inflammatory properties via in patients with bronchitis, although they may be of benefit to the improvement of mucociliary clearance and the reduction this population in other ways. Actually, a mucolytic drug of chemokines from epithelial cells. Finally, a sort of ‘‘sen- could exert antitussive effects if it also affects mucus con- sitization’’ of 2-adrenoceptors can also be speculated due to sistency and enhances ciliary function. In the last decade, the same mechanisms of action; if confirmed by further data from several studies on animal models pointed to the controlled studies, this particular property would suggest a possible antitussive and anti-inflammatory properties of novel therapeutic role of erdosteine in COPD.
    [Show full text]
  • Pharmacotherapy of Impaired Mucociliary Clearance in Non-CF Pediatric Lung Disease
    Pediatric Pulmonology 42:989–1001 (2007) State of the Art Pharmacotherapy of Impaired Mucociliary Clearance in Non-CF Pediatric Lung Disease. A Review of the Literature 1 1 1,2 Ruben Boogaard, MD, * Johan C. de Jongste, MD, PhD, and Peter J.F.M. Merkus, MD, PhD Summary. Mucoactive agents are used to treat a variety of lung diseases involving impaired mucociliary clearance or mucus hypersecretion. The mucoactive agents studied most frequently are N-acetylcysteine (NAC), recombinant human DNase (rhDNase), and hypertonic saline. Studies on the efficacy of these have been mainly conducted in adults, and in patients with cystic fibrosis (CF). The exact role of mucoactive agents in children with non-CF lung disease is not well established. We present an overview of the current literature reporting clinical outcome measures of treatment with NAC, rhDNase, and hypertonic saline in children. Pediatr Pulmonol. 2007; 42:989–1001. ß 2007 Wiley-Liss, Inc. Key words: mucolytic; sulfhydryl compounds; N-acetylcysteine; dornase alfa; hyper- tonic saline; respiratory tract disease. INTRODUCTION One possible means to evaluate a mucoactive agent is to assess its effect on mucociliary clearance (MCC) or cough Mucus clearance is an important primary innate airway clearance with the use of radiolabeled aerosol. Discussing defense mechanism, and our understanding of the key this subject is outside the scope of this review. Moreover, parameters underlying its function has grown rapidly in the studies on mucoactive agents in CF patients, and studies last decade.1,2 Impaired mucus clearance or mucus hyper- on physiotherapy or secretion clearance techniques in secretion are important clinical features in diseases such as (pediatric) lung disease patients have been reviewed by cystic fibrosis (CF), recurrent bronchitis, asthma, and others, and will therefore not be discussed in this review.
    [Show full text]